Akesis Pharmaceuticals

Akesis Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic disorders, particularly Type 2 diabetes. The company's lead candidate, AKP-020, was a vanadium-based small molecule designed to act as an insulin mimetic by inhibiting protein tyrosine phosphatases and enhancing insulin receptor signaling. While AKP-020 reached Phase 2a clinical trials and showed promise in improving glycemic control, the company faced significant financial constraints. Akesis eventually ceased active clinical development and operations in the late 2000s. The company was headquartered in La Jolla, California, and was publicly traded on the OTC markets.